Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company has a strategic alliance with SOPHiA GENETICS SA for the development of liquid biopsy companion diagnostic (CDx) test. The co
The current price of MYGN is $4.66 USD — it has decreased by -3.92% in the past 24 hours. Watch Myriad Genetics stock price performance more closely on the chart.
What is Myriad Genetics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Myriad Genetics stocks are traded under the ticker MYGN.
Is Myriad Genetics stock price growing?▼
MYGN stock has fallen by -3.12% compared to the previous week, the month change is a +3.79% rise, over the last year Myriad Genetics has showed a -53.72% decrease.
What is Myriad Genetics market cap?▼
Today Myriad Genetics has the market capitalization of 435.75M
When is the next Myriad Genetics earnings date?▼
Myriad Genetics is going to release the next earnings report on April 30, 2026.
What were Myriad Genetics earnings last quarter?▼
MYGN earnings for the last quarter are 0.04 USD per share, whereas the estimation was -0.01 USD resulting in a +367.97% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Myriad Genetics revenue for the last year?▼
Myriad Genetics revenue for the last year amounts to 1.65B USD.
What is Myriad Genetics net income for the last year?▼
MYGN net income for the last year is -731.8M USD.
How many employees does Myriad Genetics have?▼
As of March 16, 2026, the company has 2,700 employees.
In which sector is Myriad Genetics located?▼
Myriad Genetics operates in the Health Care sector.
When did Myriad Genetics complete a stock split?▼
The last stock split for Myriad Genetics was on March 26, 2009 with a ratio of 2:1.
Where is Myriad Genetics headquartered?▼
Myriad Genetics is headquartered in Salt Lake City, US.